Prontuario delle Formulazioni Galeniche per Malattie Rare Pagina 1

Prontuario delle Formulazioni Galeniche per Malattie Rare
Nome Medicinale Galenico
Acido acetilsalicilico 20 mg
Baclofene 1 mg
Baclofene 300 mg
Betaina base 1200 mg
Bicarbonato di sodio 8,4%
Conf.
30
30
30
Forma Farm.
Indicazione Terapeutica
capsule
Sindrome di Kawasaki
cartine
disturbi del metabolismo
e degli
amminoacidi/cistinuria
capsule
corea di Huntington
Cod. Pat. Rara
Asl / Aso
Letteratura a supporto
Cod.Region.
Galenico
Atc
Tariffa (€)
C01E
8,1
8,4
RG0040
ASL TO 3
Treatment of acute Kawasaki
disease: aspirin's role in the
febrile stage revisited.Hsieh
KS, Weng KP, Lin CC, Huang GROCRG001
TC, Lee CL, Huang SM.
Pediatrics.
2004
Dec;114(6):e689-93.
RCG040
ASL TO 2
Giovanni
Bosco
"Orally administered drugs in
the treatment of spasticity"
GROCRC002
Campistol J.1: Rev Neurol.
2003 Jul 1-15;37(1):70-4.
A16A
ASL TO 2
Giovanni
Bosco
A controlled clinical trials of
baclofen as protective therapy
in early Huntington's disease.
GROCRF003
Shoulson I et al. Ann Neurol.
1989 Mar;25(3):252-9. PMID:
2524992
N07
RF0080
30
cartine
omocistinuria
RCG040
ASL NO
1L
soluzione
acquosa
tubulopatia renale
congenita
RJG011- codice
esenzione valido
solo per la
Regione Piemonte
ASL BI
Pagina 1
Wilcken, D. E. L.; Wilcken, B.;
Dudman, N. P. B.; Tyrrell, P.
A.
:Homocystinuria--the
effects of betaine in the
treatment of patients not GROCRC004
responsive to pyridoxine. New
Eng. J. Med. 309: 448-453,
1983.
Manuale Merck- Anomalie
congenite - anomalie nel
trasporto renale
GROSRJ005
A16A
9
G04B
5
Prontuario delle Formulazioni Galeniche per Malattie Rare
Capsaicina 31,25 mg
Ciclosporina 0,5%
Citrullina 500 mg
Clobetasolo 0,5mg in
idrossietilcellulosa 4%
anaparti
30 /
100
10 ml
30
100 g
"Preliminary
protocol
for
systemic administration of
capsaicin for the treatment of
the burning mouth syndrome"
Lauritano D, Petruzzi M, GROCRM006
Baldoni M., Minerva Stomatol.
2003 Jun;52(6):273-8.
capsule
sclerodermia (sclerosi
sistemica progressiva)
RM0091 - codice
esenzione valido
solo per la
Regione Piemonte
ASL TO 2
Giovanni
Bosco
collirio
pemfigoide benigno
delle mucose
RL0030
ASL VC
Vercelli
Manuale Merck - Affezioni
dermatologichemalattie
bollose
ASL NO
capsule
unguento
intolleranza alle proteine
con lisinuria
pemfigo orale
RCG040
RL0030
Pagina 2
D11
8,50 (30 cps) / 17,8
(100cps)
GRFSRL007
S01X
18,5
Mizutani N, Kato T, Maehara
M, Watanabe K, Ban M. "Oral
administration of arginine and
citrulline in the treatement of GROCRC008
lysinuric
protein
intollerance."Tohoku J Exp
Med.1984 Jan;142(1):15-24
A12C
11,2
D11
13,8
A
Comparison
of
Two
Regimens
of
Topical
Corticosteroids
in
the
Treatment of Patients with
Bullous
Pemphigoid:
A
AOU S.
Multicenter
Randomized
Giovanni
Study.Joly P, et al -J Invest
Battista, ASL
Dermatol. 2009 Jan 29.
19 AT, ASO
doi:10.1038/jid.2008.412.
Maggiore
The
role
of
topical
della Carità
corticosteroids
in
bullous
Novara
pemphigoid in the elderly.Joly
P, Fontaine J, Roujeau JC. Drugs Aging. 2005;22(7):5716.
GRTPRL009
Prontuario delle Formulazioni Galeniche per Malattie Rare
Creatina 0,5 g
100
Creatina Monoidrata 1 g
Creatina 2 g – 3 g
30
30 /
90
cartine, capsule
cartine
cartine
atrofia muscolare
spinale, sindrome di
Werdnig-Hoffman
miopatia congenita
ereditaria
distrofia muscolare
(es.Distrofia muscolare
di Duchenne)
RFG050
“Creatine for treating muscle
disorders” Kley, R.A. The
Cochrane
Library,
2007.
“Clinical use of creatine in
ASL 19 AT
GROCRF010
neuromuscolar
and
neurometabolic
disorders”
Tarnopolosky MA. Subcell
Biochem.2007;46:183-204.
M09
19
RFG070
Shefner JM, et al. A clinical
trial
of
creatine
in
ALS.Neurology 2004;63:165661. Persky AM, Brazeau GA.
Clinical pharmacology of the
dietary supplement creatine GROCRF011
monohydrate. Pharmacol Rev
2001;53:161-76.
www.farmacovigilanza.orgImpiego terapeutico creatina
orale.
M09
8,5
"Creatine May Help Muscular
Dystrophy- Researchers Say
the Nutritional Supplement
May
Improve
Muscle
Strength" Kley, R.A. The
Cochrane Library, 2007.
"Creatine monohydrate as a
ASL TO 2
therapeutic aid in muscular
Giovanni
dystrophy", Pearlman JP, GROCRF012
Bosco, ASL
Fielding RA., Nutr Rev. 2006
TO 3
Feb;64(2 Pt 1):80;
Clinical use of creatine in
neuromuscular
and
neurometabolic
disorders.Tarnopolsky
MA.
Subcell
Biochem.
2007;46:183-204.
M09
8,9 (3 g 30 cartine) /
10,5 (2 g 30 cartine) /
23,7(2 g 90 cartine)
RFG080
Pagina 3
ASL TO 2
Maria
Vittoria
Prontuario delle Formulazioni Galeniche per Malattie Rare
Creatina 2 g
Creatina 2,5 g
30
30
cartine
cartine
neuropatie ereditarie
SLA
RFG060
RF0100
Pagina 4
ASL TO 3
Resistance training exercise
and creatine in patients with
Charcot-Marie-Tooth disease.
Chetlin RD, Gutmann L, GROCRF013
Tarnopolsky MA, Ullrich IH,
Yeater RA.Muscle Nerve.
2004 Jul;30(1):69-76.
N07
8,5
ASL TO 3
Creatine and its potential
therapeutic value for targeting
cellular energy impairment in
neurodegenerative diseases.
Adhihetty
PJ,
Beal
MF.Neuromolecular
Med.
2008;10(4):275-90
Creatine monohydrate in ALS:
effects on strength, fatigue, GROCRF014
respiratory
status
and
ALSFRS.
Rosenfeld J, King RM,
Jackson CE, Bedlack RS,
Barohn RJ, Dick A, Phillips
LH, Chapin J, Gelinas DF,
Lou JS. Amyotroph Lateral
Scler. 2008 Oct;9(5):266-72.
N07
8,7
Prontuario delle Formulazioni Galeniche per Malattie Rare
DMSO 15% in crema base
EDTA colliro 0,05 M
500 g
20 ml
pomata
collirio
amiloidosi
cheratite a bandelletta
RCG130
ASL TO 2
Giovanni
Bosco
"Intermittent use of topical
dimethyl sulfoxide in macular
and papular amyloidosis"
Ozkaya-Bayazit E, Kavak A,
Gungor H, Ozarmagan G,
International
Journal
of
Dermatology 1998; 37:949954;
"Multidisciplinary utilization of
dimethyl
GRTPRC015
sulfoxide:pharmacological,
cellular,
and
molecular
aspects" Santos NC, FigueiraCoelho J, Martins-Silva J,
Saldanha C, Biochemical
Pharmacology 2003; 65:10351041;
"Medical use of dimethyl
sulfoxide " Swanson BN,
Rev. Clin. Basic Pharm.
1985;5(1-2):1-33.
RN1500
A.S.O. S.
Croce e
Carle
EDTA chelation for calcific
band keratopathy: results and
long-term
follow-up.Najjar GRFSRN016
DM,et al - Am J Ophthalmol.
2004 Jun;137(6):1056-64.
Pagina 5
D11
22
S01X
5,3
Prontuario delle Formulazioni Galeniche per Malattie Rare
Fludrocortisone 0,0001 mg
Glicerolato d'amido 10% in
vaselina
100
500 g
capsule
crema
Adrenoleucodistrofia
RF0120
ASL TO 3
Adrenal
steroids
in
adrenomyeloneuropathy.
Dehydroepiandrosterone
sulfate, androstenedione and
17alphahydroxyprogesterone.
Wichers-Rother M, Grigull A,
Sokolowski P, Stoffel-Wagner
B, Köhler W. J Neurol. 2005
Dec;252(12):1525-9.
GROCRF017
X-linked
adrenoleukodystrophy is a
frequent cause of idiopathic
Addison's disease in young
adult male patients. Laureti S,
Casucci G, Santeusanio F,
Angeletti G, Aubourg P,
Brunetti P. J Clin Endocrinol
Metab. 1996 Feb;81(2):470-4.
ASL TO 2
Giovanni
Bosco, AOU Medicamenta
S. Giovanni
Battista
M09
12
GRTPRN018
D11
19,4
ittiosi congenita
RNG070
ASL TO 2
Maria
Vittoria
How I treat…pityriasis rubra
pilaris. Fraiture AL, Braham
C, Pierard-Franchimont C,
Pierard GE. - Rev Med
Liege.2002 Jun;57(6):363-5
GRTPRL019
D11
18,9
ASL TO 2
Giovanni
Bosco
Medicamenta
GRTPRN052
D11
32,8
Glicerolato d'amido 10% in
vaselina filante
500 g
unguento
pitiriasi rubra pilaris
RL0081- codice
esenzione valido
solo per la
Regione Piemonte
Glicerolato d'amido 10% in
dermo base grassa
500 g
crema
ittiosi congenita
RNG070
Pagina 6
Prontuario delle Formulazioni Galeniche per Malattie Rare
Levodopa/carbidopa dosaggi
vari (pro chilo)
Miscela di fosfati (1 ml/41 mg
di P)
Miscela di fosfati
aromatizzata al cacao
30
1L
1L
cartine
soluzione
soluzione
difetto di
tetraidrobiopterina da
deficit di ptps
tubulopatia renale
congenita
rachitismo
ipofosfatemico vitamina
d resistente
RCG040
RJG011- codice
esenzione valido
solo per la
Regione Piemonte
RC0170
Pagina 7
A.S.O. S.
Croce e
Carle
Disorders
of
tetrahydrobiopterin
metabolism
and
their
GROCRC020
treatment. Shintaku H. - Curr
Drug
Metab.
2002
Apr;3(2):123-31.
ASL NO
Manuale Merck- Anomalie
congenite - anomalie nel
trasporto renale
Pharmacotherapy
A
pathophysiological approche
7th edition 2008 -Dipiro J T,
Talbert RL
ASL BI
Bouillon R et al, Intestinal
calcium absorption: molecular
vitamin
D
mediated
mechanism, J Cell Bioch
2003; 88: 332-9
Rowe PSN, The molecular
background
to
hypophosphatemic
rickets,
Arch Dis Child 2000; 83: 1924
GROSRC022
Baroncelli G et al, Effect of
GH treatment on final height,
phosphate metabolism, and
BMD in children with X-linked
hypophosphatemic rickets, J
Pediatr 2001; 138: 236-43
Harrison Principi di Medicina
Interna, 16° edizione, volume
II, pag. 1917
GROSRJ021
N07
8
G04B
9
A11CC
9,9
Prontuario delle Formulazioni Galeniche per Malattie Rare
Mometasone furoato in
dermo base grassa
Nifedipina AR 20mg
Oxitriptano dosaggi vari (pro
chilo)
Piridostigmina bromuro 34
mg
60 g /
120 g
100
30
30
crema
pemfigo
RL0060
ASL TO 2
Giovanni
Bosco
capsule
iperaldosteronismo
primitivo (con
ipertensione)
RCG010
ASL TO 2
Maria
Vittoria
cartine
difetto di
tetraidrobiopterina da
deficit di ptps
RCG040
capsule
miastenia gravis
RFG171-codice
esenzione valido
solo per la
Regione Piemonte
Pagina 8
A
Comparison
of
Two
Regimens
of
Topical
Corticosteroids
in
the
Treatment of Patients with
Bullous
Pemphigoid:
A
Multicenter
Randomized
Study.Joly P, et al -J Invest
Dermatol. 2009 Jan 29.
doi:10.1038/jid.2008.412.
The
role
of
topical
corticosteroids
in
bullous
pemphigoid in the elderly.Joly
P, Fontaine J, Roujeau JC. Drugs Aging. 2005;22(7):5716.
D11
15,4 (60g) / 24,4 (120
g)
Scheda Tecnica di Adalat AR
GROCRC054
20 mg cp.
C03DA
8
A.S.O. S.
Croce e
Carle
Disorders
of
tetrahydrobiopterin
metabolism
and
their
GROCRC023
treatment. Shintaku H. - Curr
Drug
Metab.
2002
Apr;3(2):123-31.
N07
10,5
ASL TO 2
Maria
Vittoria
Diagnostic and treatment of
myasthenia gravis in children.
Kroczka S,Steczkowska
M,Nowak A,Kacinski M. Przegl Lek. 2008;65(11):7838.
Myastenia gravis. Fleury MC,
Tranchant C. Rev Prat. 2008
Dec 31;58(20):2217-24.
M09
9,8
GRTPRL028
GROCRF024
Prontuario delle Formulazioni Galeniche per Malattie Rare
Potassio Canrenoato 6,25
mg
Potassio citrato 3g – 5g
Propranololo 3-7-9-15 mg
30
30
30
capsule
cartine
capsule
iperaldosteronismo
primitivo
Cistinuria
RCG010
RCG040
ASL TO 2
Maria
Vittoria
Primari hyperaldosteronism:
from diagnosis to treatment.
Wemeau JL, Mounier-Vehier
C,Carnaille B,Douillard C. Press
Med.2009
Apr;38(4):633-42.Epub 2009
Mar
18.
Idiopatic
primary
hyperaldosteronism:normaliza GROCRC025
tion of plasma aldosteronereceptor antagonist potassium
canrenoate.
Armanini
D,Scaroni
C,Mattarello
MJ,Fiore
C,Albiger
N,Sartorato P J Endocrinol
Invest. 2005 Mar;28(3):23640.
C03DA
8,6
ASL TO 3
Renal stone disease: Causes,
evaluation
and
medical
treatment.Heilberg IP, Schor
GROCRC026
N.Arq
Bras
Endocrinol
Metabol. 2006 Aug;50(4):82331.
C03D
8,6 (3g) / 9,1 (5 g)
C
8,7
ASL TO 2
Giovanni
RNG111 - codice
Bosco, ASL
gravi anomalie
Manuale Merck - Pediatria esenzione valido
GROCRN027
TO 4, ASO
congenite senza ritardo
Anomalie congenite
solo per la
Maggiore
mentale
Regione Piemonte
della Carità
Novara
Pagina 9
Prontuario delle Formulazioni Galeniche per Malattie Rare
Quercetina 175
mg/bromelina 60 mg/papaina
60 mg
Quercetina 175
mg/condroitina solfato 60
mg/glucosamina solfato 60
mg
Quercetina 100
mg/condroitina solfato 125
mg/glucosamina solfato 125
mg/rutina 12,5 mg/sodio
ialuronato 7,25 mg
100
100
100
capsule
capsule
capsule
cistite interstiziale
cistite interstiziale
cistite interstiziale
RJ0030
"Treatment
of
Interstitial
Cystitis with a Quercetin
ASL VC
Supplement
(Cysta-Q)"
Vercelli, ASL
Katske F, Shoskes DA,
CN 1
Sender
M,
Poliakin
R, GROCRJ053
Mondovì,
Gagliano
K,
Rajfer
J.
ASL NO,
Techniques in Urology 7(1):44ASL TO 4
46, March 2001
RJ0030
RJ0030
Pagina 10
ASL VC
Vercelli
ASL NO
Treatment
of
refractory
interstitial
cystitis/painful
bladder
syndrome
with
CystoProtek--an oral multi- GROCRJ029
agent natural supplement.
Theoharides T C et al. Can. J.
Urol.2008 Dec;15(6):4410-4
Treatment
of
refractory
interstitial
cystitis/painful
bladder
syndrome
with
CystoProtek--an oral multiGROCRJ030
agent natural supplement.
Theoharides T C et al. Can. J.
Urol.2008 Dec;15(6):4410-4
G04B
23
G04B
21,5
G04B
27
Prontuario delle Formulazioni Galeniche per Malattie Rare
Riboflavina 50 mg
30 /
100
capsule/cartine
sindrome di Melas
RN0170
Pagina 11
ASL NO,
ASL TO 2
Giovanni
Bosco
MELAS di Salvatore DiMauro,
MD, attraverso GENEReviews
www.genetests.org
MELAS
Syndrome
di
Fernando
Scaglia,
MD
articolo di eMedicine
http://www.emedicine.com/pe
d/topic1406.htm
MELAS Syndrome di Mary
Kugler MSN, RN, Bc
http://rarediseases.about.com
/cs/melassyndrome/a/021204.
htm
Strokes e Transient Events in
Mitochondrial cytopathies di
Bruce cohen, MD
Articolo
in
Pensa
ai
GROCRN031
mitocondri,
compendium,
disponibile attraverso UMDF
"MELAS
syndrome
with
mitochondrial
tRNA(Leu)(UUR)
mutation:
correlation of clinical state,
nerve conduction, and muscle
31P magnetic resonance
spectroscopy
during
treatment with nicotinamide
and riboflavin." Penn AM, Lee
JW, Thuillier P, Wagner M,
Maclure KM, Menard MR, Hall
LD,
Kennaway
NG.,
Neurology.
1992
Nov;42(11):2147-52.
"Long-term treatment with ideb
N07
8,7 (30 cps) / 18,2
(100cps)
Prontuario delle Formulazioni Galeniche per Malattie Rare
Riboflavina 50 mg – 60mg
Riboflavina 50 mg
30
30
cachets
capsule
neuropatia ottica
ereditaria
Malattia di Leigh
RF0300
RF0030
Pagina 12
ASL TO 2
Maria
Vittoria
ASL TO 3
Neurochemistry International
40 (2002) 573–584
Optic nerve degeneration and
mitochondrial
dysfunction:genetic
and
acquired optic neuropathies
Valerio Carelli
, Fred N.
GROCRF032
Ross-Cisneros, Alfredo A.
Sadun
Doheny Eye Institute, USC
Keck School of Medicine,
DVRC 311, 1355 San Pablo
Street, Los Angeles, CA
90033, USA
Accepted 30 October 2001
[Leigh
syndrome
and
leukodystrophy due to partial
succinate
dehydrogenase
deficiency: regression with
riboflavin]Pinard JM, Marsac
GROCRF033
C, Barkaoui E, Desguerre I,
Birch-Machin M, Reinert P,
Ponsot G.Arch Pediatr. 1999
Apr;6(4):421-6.
N07
8,1
N07
8,2
Prontuario delle Formulazioni Galeniche per Malattie Rare
Riboflavina 100 mg
Salbutamolo 2 mg
Sildenafil 2,5 mg
30
30
30
capsule
capsule
cartine
alterazioni congenite del
metabolismo delle
lipoproteine
Atrofie muscolari spinali
mucolipidosi tipo II
RCG070
RFG050
RCG090
Pagina 13
ASL TO 3
Riboflavin-Responsive
Metabolic
Myopathy
with
Abnormal
Fatty
Acid
Oxidation
and
Defective
Intramitochondrial Respiratory
Complexes.
Lodovica
Vergani, Flavio Collatuzzo,
Giuliana
Schievano
and
Corrado Angelini. BAM 6 (2):
135-138,1996.
Riboflavin-Theraphy.
GROCRC034
Biochemical heterogeneity in
two
adult
lipid
storage
myopathies.
Lodovica
Vergani,
Maria
Barile,
Corrado Angelici, Alberto B.
Burlina,Leo Nijtmans, Maria
Pia Freda, Carmen Brizio,
Elisabetta
Zerbetto
and
Federica Dabbeni-Sala. Brain
(1999), 122, 2401-2411.
C10A
8,5
ASL NO
Daily salbutamol in young
patients with SMA type II,
Neuromuscul
Disord.2008 GROCRF035
Jul;18(7):536-40. Epub 2008
Jun 24
M09
8
ASL BI
The use of Sildenafil in
Persistent
Pulmonary
Hypertension of the Newborn Vargas-Origel et Al.-Am J
Perinatal
2009
Oct.28
GROCRC036
Sildenafil for the Tratment of
Pulmonary Hypertension in
pediatric Patients-Huddleston
et Al.-Pediatric Cardiology
Vol.30 (2009)
C10A
25
Prontuario delle Formulazioni Galeniche per Malattie Rare
Sodio cloruro 250 mg
Soluzione di joulie
Tiamina 150 mg
30
500 ml
30
cartine
tubulopatia renale
congenita
soluzione
rachitismo
ipofosfatemico vitamina
d resistente da
sindrome FanconiBickel
capsule
Malattia di Leigh
RJG011- codice
esenzione valido
solo per la
Regione Piemonte
ASL NO
Harrison Principi di Medicina
Interna, 16° edizione, volume GROCRJ037
II, pag. 1917
G04B
7,9
RC0170
ASL 19 AT,
ASO
Maggiore
della Carità
Novara
Norme di buona preparazione
galenica
200;201
M.
GROSRC038
Corsi,G.Masoni;L.Manechia;C
. Cassano
A11CC
9,1
ASL TO 3
Outcome
of
thiamine
treatment in a child with Leigh
disease due to thiamineresponsive
pyruvate
dehydrogenase deficiency.
Di Rocco M, Lamba LD,
Minniti G, Caruso U, Naito E.
Eur J Paediatr Neurol.
2000;4(3):115-7.
GROCRF039
Pyruvate
dehydrogenase
deficiency
in
a
child
responsive
to
thiamine
treatment.
Pastoris
O,
Savasta
S,
Foppa
P,
Catapano M, Dossena M.
Acta
Paediatr.
1996
May;85(5):625-8.
N07
8,2
RF0030
Pagina 14
Prontuario delle Formulazioni Galeniche per Malattie Rare
Ubidecanrenone 250-300 mg
Ubidecarenone 300 mg
30 /
100
30
capsule
capsule
sindrome di Melas
SLA
RN0710
RF0100
Pagina 15
ASL TO 2
Giovanni
Bosco
"Coenzima Q e malattie
mitocondriali: dalla biochimica
alle
implicazioni
terapeutiche"Toscano
A,
Musumeci O, Neurol Sci
2004;25:S317-319;
"Muscle
coenzyme
Q10
concentrations in patients with
probable
and
definite
diagnosis of respiratory chain
disorders" Montero R , Artuch
R, Briones P, Nascimento A
et al Biofactors, 2005; 25(1- GROCRN040
4):109-15;
"Cerebellar
ataxia
with
coenzyme Q10 deficiency :
diagnosis and follow-up after
coenzyme
Q10
supplementation" Artuch R,
Brea- Calvo G, Briones P,
Aracil A et al. J Neurol Sci
2006;246 (1-2):153-8.
“A two-stage design for a
phase II clinical trial of
coenzyme Q10 in ALS” Levy
G, Neurology. 2006 Mar
14;66(5):660-3
“Tolerance of high-dose
ASO
Maggiore (3,000 mg/day) coenzyme
della Carità Q10 in ALS” Ferrante KL;
Novara,
Neurology 2005 Dec
ASL TO 3 13;65(11):1834-6
“Neuroprotective agents for
clinical trials in ALS: a
systematic assessment”
Traynor BJ. Neurology. 2006
Jul 11;67(1):20-7
GROCRF041
N07
16,2 (250mg 30 cps) /
42 (250 mg100cps) /
17 (300 mg 30 cps) /
46,3 (300mg 100cps)
N07
17
Prontuario delle Formulazioni Galeniche per Malattie Rare
Ubidecarenone 1000mg (alto
dosaggio)
Ubidecarenone 300 mg
30
30 /
100
cachets
capsule
SLA
corea di Huntington
RF0100
RF0080
Pagina 16
ASL TO 2
Maria
Vittoria
ASL TO 2
Giovanni
Bosco
“Tolerance
of
high-dose
(3,000 mg/day) coenzyme
Q10 in ALS” Ferrante KL; GROCRF042
Neurology
2005
Dec
13;65(11):1834-6
"Coenzyme Q10: a review of
its
promise
as
a
neuroprotectant" Young AJ,
Johnson S, Steffens DC,
Doraiswamy
PM.,
CNS
Spectr. 2007 Jan;12(1):62-8.
"Coenzyme
Q10
GROCRF043
administration
and
its
potential for treatment of
neurodegenerative
diseases.", Beal MF., 1:
Biofactors. 1999;9(2-4):261-6.
N07
86,6
N07
17 (30 cps) / 46,3
(100cps)
Prontuario delle Formulazioni Galeniche per Malattie Rare
Ubidecarenone 300 mg /
600 mg
Urea 10%,ac.lattico 5% in
crema base magra
30 /
50
500 g
cachets
crema
miopatia mitocondriale
ittiosi congenita
A.S.O. S.
Croce e
Carle
RN0710
RNG070
"Coenzima Q e malattie
mitocondriali: dalla biochimica
alle
implicazioni
terapeutiche"Toscano
A,
Musumeci O, Neurol Sci
2004;25:S317-319;
"Muscle
coenzyme
Q10
concentrations in patients with
probable
and
definite
diagnosis of respiratory chain
disorders" Montero R , Artuch
GROCRN044
R, Briones P, Nascimento A
et al Biofactors, 2005; 25(14):109-15;
"Cerebellar
ataxia
with
coenzyme Q10 deficiency :
diagnosis and follow-up after
coenzyme
Q10
supplementation" Artuch R,
Brea- Calvo G, Briones P,
Aracil A et al. J Neurol Sci
2006;246 (1-2):153-8.
Improved topical treatment of
lamellar ichthyosis: a doubleblind study of four different
cream formulations.- Ganemo
A,Virtanen M,Vahlquist A. - Br
ASL TO 2
J
Dermatol.
1999
Maria
Dec;141(6):1027-32.
GRTPRN045
Vittoria, ASL
Ichthyosis:
clinical
TO 3
manifestations and practical
treatment options.
Oji V, Traupe H.Am J Clin
Dermatol. 2009;10(6):351-64.
Pagina 17
N07
35,2 (300mg) / 102
(600mg 50 cachets) /
63 (600mg 30
cachets)
D11
22,3
Prontuario delle Formulazioni Galeniche per Malattie Rare
Urea 10% Glicerolo 5%
Crema base
Urea 5% Glicerolo 5% Crema
base
Urea 5% Glicerolo 5% Crema
base q.b. 1 kg
500 g
500 g
1000 g
crema
crema
crema
Ittiosi congenita
Ittiosi congenita
Lichen Sclerosus et
Atrophicus
RNG070
Improved topical treatment of
lamellar ichthyosis: a doubleblind study of four different
ASL TO 2 cream formulations.- Ganemo
Maria
A,Virtanen M,Vahlquist A. - Br
Vittoria, ASL J
Dermatol.
1999
TO 2
Dec;141(6):1027-32.
GRTPRN046
Giovanni Ichthyosis:
clinical
Bosco, ASL manifestations and practical
TO 3
treatment options.
Oji V, Traupe H.Am J Clin
Dermatol. 2009;10(6):351-64.
RNG070
RL0060
Pagina 18
ASL TO 2
Maria
Vittoria
ASL TO 3
Improved topical treatment of
lamellar ichthyosis: a doubleblind study of four different
cream formulations.- Ganemo
A,Virtanen M,Vahlquist A. - Br
J
Dermatol.
1999
Dec;141(6):1027-32.
GRTPRN047
Ichthyosis:
clinical
manifestations and practical
treatment options.
Oji V, Traupe H.Am J Clin
Dermatol. 2009;10(6):351-64.
Lichen
Sclerosus
et
Atrophicus, bullous morphea,
and
systemic
lupus
erythematosus: a case report.
Kuan-Hsun Wu, Yang-Shia
Dai, Ming-Jer Tsai, ShihChiang Lin, Ling-Hua Wang,
Miao-Tsu Huamg, Bor-Luen
Chiang. J Microbiol Immunol
Infect. 2000;33:53-56.
GRTPRL055
D11
19
D11
17,7
D11
34,8
Prontuario delle Formulazioni Galeniche per Malattie Rare
Urea 30% in crema base
magra
Urea 5% in vaselina bianca
Vaselina salicilica unguento
10%
500 g
500 g
500 g
crema
cheratodermia palmoplantare (ipercheratosi
epidermica)
Hereditary
Palmoplantar
Keratodermas.Braun-Falco M
.- J Dtsch Dermatol Ges.
2009 Apr1.[Epub ahead of
print].
GRTPRN048
Water content of the skin
following salicylic acid and
urea treatment. - Racz I,Soos
G,Jakab E. - Hautarzt.198940
Suppl 9:61-2.
D11
18
crema
Lichen
Sclerosus
et
Atrophicus, bullous morphea,
and
systemic
lupus
RM0091- codice ASL TO 3, erythematosus: a case report.
sclerodermia (sclerosi esenzione valido
AOU S.
Kuan-Hsun Wu, Yang-Shia
GRTPRM049
sistemica progressiva)
solo per la
Giovanni Dai, Ming-Jer Tsai, ShihRegione Piemonte
Battista
Chiang Lin, Ling-Hua Wang,
Miao-Tsu Huamg, Bor-Luen
Chiang. J Microbiol Immunol
Infect. 2000;33:53-56.
D11
15,2
D11
16,5
crema
Ittiosi congenita
RN0600
RNG070
Pagina 19
ASL TO 2
Maria
Vittoria
ASL TO 3
Ichthyoses
Part
1:
Differential diagnosis of vulgar
ichthyoses and therapeutic
GRTPRN050
options.Krug M, Oji V, Traupe
H, Berneburg M.J Dtsch
Dermatol
Ges.
2009
Jun;7(6):511-9.
Prontuario delle Formulazioni Galeniche per Malattie Rare
Vaselina salicilata 20%
500 g
unguento
cheratodermia palmoplantare (ipercheratosi
epidermica)
RN0600
Pagina 20
ASL TO 2
Maria
Vittoria
Hereditary
Palmoplantar
Keratodermas.Braun-Falco M
.- J Dtsch Dermatol Ges.
2009 Apr1.[Epub ahead of
print].
GRTPRN051
Water content of the skin
following salicylic acid and
urea treatment. - Racz I,Soos
G,Jakab E. - Hautarzt.198940
Suppl 9:61-2.
D11
18,5